Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T5036 |
cangrelor tetrasodium
|
GPR; P2Y Receptor | Endocrinology/Hormones; GPCR/G Protein; Neuroscience |
Cangrelor tetrasodium 是三磷酸腺苷类似物,是可逆的选择性血小板P2Y12拮抗剂,也是非特异性的GPR17拮抗剂。它直接阻断腺苷二磷酸诱导的血小板活化和聚集,具有迅速有效的抗血小板作用。 | |||
T70335 | Cangrelor free acid | ||
Cangrelor is a P2Y12 inhibitor, and was approved in June 2015 as an antiplatelet drug for intravenous application. Cangrelor is a high-affinity, reversible inhibitor of P2Y12 receptors that causes almost complete inhibition of ADP-induced platelet aggregate. It is a modified ATP derivative stable to enzymatic degradation. It does not require metabolic conversion to an active metabolite. This allows cangrelor’s immediate effect after infusion, and the therapeutic effects can be maintained with... |